Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of YYD601 vs Nexium in Healthy Male Volunteers
NCT03558477Phase 1Completed
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YYD601 in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoints: Half-life at 5 days, Time to Maximum Concentration at 5 days and 2 more. Started Sep 2017; status: completed.
02
Drugs
YYD601
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03558477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558477.